Orris

Treatment for distal rta

Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed

"renal tubular acidosis" AND treatment

Searching the Web

distal renal tubular acidosis treatment alkali potassium citrate guideline

Reading File
Distal renal tubular acidosis (type 1 dRTA) is treated primarily with oral alkali replacement to correct chronic normal-anion-gap metabolic acidosis, hypokalemia, hypocitraturia, stones/nephrocalcinosis, and bone disease.
  • Preferred agent: potassium citrate, especially with hypokalemia, kidney stones, nephrocalcinosis, or hypocitraturia. It supplies alkali and potassium and increases urinary citrate.
  • Alternatives: sodium bicarbonate, sodium citrate, or potassium bicarbonate. Sodium-based alkali is more useful when potassium is high or potassium citrate is contraindicated.
  • Typical total alkali requirement:
    • Adults: 1-2 mEq/kg/day
    • Children: 3-6 mEq/kg/day, often higher in infancy or severe inherited dRTA
      Give in divided doses and titrate to normal serum bicarbonate and potassium. Goldman-Cecil Medicine International Edition, p. 1312.
  • Correct significant hypokalemia early, often with potassium citrate or additional potassium supplementation. Severe hypokalemia may need urgent supervised replacement and ECG monitoring.
  • Treat the cause in acquired dRTA, for example Sjögren syndrome, autoimmune tubulointerstitial nephritis, medication/toxin exposure, or obstruction, while continuing alkali therapy.
  • Manage complications: adequate hydration; evaluate/treat calcium-phosphate stones and nephrocalcinosis; assess growth in children and bone disease in adults. Calcium/vitamin D may be needed only when indicated for rickets/osteomalacia.
Monitoring: serial serum bicarbonate/total CO₂, potassium, chloride, creatinine/eGFR, urine pH/citrate, and stone burden. The aim is normal acid-base status, normal potassium, prevention of stones, and normal growth in children. The National Kidney Foundation overview similarly lists alkali agents as the main therapy.
Do not self-start potassium citrate if there is impaired kidney function, hyperkalemia, or use of drugs that raise potassium, such as ACE inhibitors, ARBs, spironolactone, or trimethoprim, without clinician supervision.
This is a shared conversation. Sign in to Orris to start your own chat.